AI Summary
ProQR reported positive Phase 1 data for AX-0810, showing dose-dependent NTCP engagement with up to 8x increases in serum bile acids at 6 mg/kg and no serious adverse events. The 8-week half-life supports sustained activity and reinforces the NTCP program’s potential. Key upcoming milestones include AX-0811 CTA in mid-2026, a China IIT in biliary atresia in 2027, and potential Phase 2 timing mid-2027.
Sentiment Rationale
Strong biomarker-driven NTCP engagement validates the mechanism; multiple near-term catalysts (AX-0811 CTA, China IIT) could drive upside sentiment, though outcomes depend on subsequent safety/efficacy data and regulatory progression.
Trading Thesis
Near-term bullish for PRQR on clear NTCP engagement data; watch AX-0811 CTA in mid-2026 and China IIT data in 2027.
Market-Moving
- AX-0810 shows up to 8x serum bile acids at 6 mg/kg, surpassing 2x target.
- CTA for AX-0811 expected mid-2026 with initial healthy volunteer data by year-end 2026.
- IIT in pediatric biliary atresia in China targeted for H1 2027; potential Phase 2 readouts in 2028.
- Pipeline expansion includes AX-0422 (IDUA) and AX-2911 (PNPLA3) advancing.
Key Facts
- AX-0810 Phase 1 shows dose-dependent NTCP engagement at 3/6 mg/kg.
- Serum bile acids up to 8x at 6 mg/kg; exceeds 2x threshold.
- No serious AEs; 8-week half-life supports sustained target engagement.
- AX-0811 CTA expected mid-2026; IIT in biliary atresia China in 2027.
Companies Mentioned
- ProQR Therapeutics N.V. (PRQR): Announces positive Phase 1 AX-0810 data; validates NTCP program and supports AX-0811/2 milestones.
- Eli Lilly and Company (LLY): Collaborative partner referenced; potential future milestones and collaborations linked to ProQR programs.
- Ginkgo Bioworks Holdings, Inc. (DNA): Partner via AI-enabled discovery; potential strategic value from AI-driven optimization of AX-0811/0810 programs.
Industry News
Industry News – a positive clinical update on a development-stage biotech with multiple downstream milestones across 2026–2028, affecting valuation sensitivity to upcoming data and regulatory steps.